Core Viewpoint - Bioventus reported quarterly earnings of $0.08 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, and showing an increase from $0.07 per share a year ago, indicating a positive earnings surprise of 33.33% [1] Financial Performance - The company achieved revenues of $123.88 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.72%, although this represents a decline from $129.46 million in the same quarter last year [2] - Over the last four quarters, Bioventus has exceeded consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - Bioventus shares have declined approximately 33.1% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.24 on revenues of $148.6 million, and for the current fiscal year, it is $0.66 on revenues of $565.01 million [7] - The estimate revisions trend for Bioventus is currently favorable, leading to a Zacks Rank 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6] Industry Context - The Medical - Drugs industry, to which Bioventus belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook for stocks within this sector [8]

Bioventus (BVS) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Company Participants Dave Crawford - VP - IR & TreasurerRobert Claypoole - CEOMark Singleton - Senior VP & CFOMichaela Smith - Equity Research Associate Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareRobert Marcus - Analyst Operator Day and welcome to the BioVentis First Quarter twenty twenty five Conference Call. All participants will be in a listen only mode. Please note this event is being record ...

First Quarter 2025 Financial Results May 6, 2025 Agenda and Speakers Rob Claypoole President and Chief Executive Officer Update on Business and 2025 Priorities Mark Singleton Senior Vice-President and Chief Financial Officer Q1 2025 Results 2025 Financial Guidance Forward Looking Statements and Use of Estimates Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchang ...

Bioventus (BVS) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Speaker0 Day and welcome to the BioVentis First Quarter twenty twenty five Conference Call. All participants will be in a listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Mr. Dave Crawford. Please go ahead, sir. Speaker1 Thanks, Chuck, and good morning, everybody, and thanks for joining us. It's my pleasure to welcome you to the BioVentis twenty twenty five first quarter earnings confere ...

```markdown [Financial Highlights](index=1&type=section&id=First%20Quarter%202025%20Financial%20Results%3A) Bioventus reported Q1 2025 revenue of $123.9 million, a 4.3% decline, with 5.0% organic growth and a narrowed net loss Q1 2025 Key Financial Metrics | Metric | Q1 2025 | Q1 2024 | Change | Organic Change* | | :--- | :--- | :--- | :--- | :--- | | **Worldwide Revenue** | $123.9M | $129.5M | -4.3% | +5.0% | | **Net Loss** | ($2.6M) | ($4.9M) | +46.9% | N/A | | **Loss per Share (GAAP)** | ($0.04) | ($0.08) | +50.0% | N/A | | **Non-GAAP EPS** | $0.08 | $0.06 | +33.3% | N/A | | **Adjusted EBITDA** | $19.2M | $22.6M | -15.0% | N/A | - The reported revenue decline was a direct result of the prior-year divestiture of the Advanced Rehabilitation Business. Excluding this, the company achieved positive organic growth across all business segments[3](index=3&type=chunk) [Revenue Analysis by Business Segment](index=2&type=section&id=Revenue%20By%20Business) Q1 2025 organic growth was positive across all segments, with Pain Treatments up 3.9% and Surgical Solutions up 7.0% Q1 2025 Revenue by Segment (in millions) | Segment | Q1 2025 Revenue | Change (Reported) | Key Driver | | :--- | :--- | :--- | :--- | | **Pain Treatments** | $58.9 | +3.9% | Double-digit growth in Durolane demand. | | **Surgical Solutions** | $45.2 | +7.0% | Double-digit growth from Ultrasonics capital equipment purchases in the U.S. | | **Restorative Therapies** | $19.7 | -35.3% | Grew 4.0% organically, driven by EXOGEN system sales execution. | Q1 2025 Revenue by Geography (in millions) | Geography | Q1 2025 Revenue | Change (Reported) | | :--- | :--- | :--- | | **U.S.** | $110.5 | -3.3% | | **International** | $13.4 | -12.0% | [Business Highlights and Full-Year 2025 Guidance](index=2&type=section&id=Recent%20Business%20Highlights) Bioventus reiterated its full-year 2025 guidance, projecting net sales of $560-$570 million and Adjusted EBITDA of $112-$116 million Full-Year 2025 Financial Guidance | Metric | Guidance Range | Implied Growth | | :--- | :--- | :--- | | **Net Sales** | $560M - $570M | ~6.1% to 8.0% (Organic) | | **Adjusted EBITDA** | $112M - $116M | ~100 bps margin growth | | **Non-GAAP EPS** | $0.64 - $0.68 | +30.6% to +38.8% | - Entered into a U.S. distribution agreement with APEX Biologix to distribute its XCELL PRP system, which expands the Pain Treatments portfolio[9](index=9&type=chunk) - Strengthened the executive leadership team with the addition of a Senior Vice-President for Surgical Solutions and a Vice-President for Strategic Accounts and Market Access[9](index=9&type=chunk) [Consolidated Financial Statements](index=7&type=section&id=Consolidated%20Financial%20Statements) This section presents the unaudited consolidated financial statements for Q1 2025, covering balance sheet, operations, and cash flows [Consolidated Balance Sheets](index=7&type=section&id=Consolidated%20balance%20sheets) As of March 29, 2025, total assets decreased to $691.4 million due to reduced cash, with liabilities also down and equity stable Balance Sheet Summary (in thousands) | Account | March 29, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Cash and cash equivalents** | $22,802 | $41,582 | | **Total current assets** | $249,367 | $275,610 | | **Total assets** | $691,414 | $727,956 | | **Total current liabilities** | $174,751 | $210,398 | | **Total liabilities** | $505,935 | $542,352 | | **Total stockholders' equity** | $185,479 | $185,604 | [Consolidated Statements of Operations](index=9&type=section&id=Consolidated%20statements%20of%20operations%20and%20comprehensive%20loss) Q1 2025 net sales were $123.9 million, with stable operating income and a reduced net loss of $2.6 million Statement of Operations Summary (in thousands) | Account | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | **Net sales** | $123,876 | $129,457 | | **Gross profit** | $83,056 | $88,380 | | **Operating income** | $4,869 | $4,928 | | **Interest expense, net** | $7,509 | $10,339 | | **Net loss attributable to Bioventus Inc.** | ($2,637) | ($4,890) | | **Loss per share** | ($0.04) | ($0.08) | [Consolidated Statements of Cash Flows](index=10&type=section&id=Consolidated%20condensed%20statements%20of%20cash%20flows) Q1 2025 net cash used in operating activities was $19.3 million, ending the quarter with $22.8 million in cash Cash Flow Summary (in thousands) | Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | **Net cash from operating activities** | ($19,331) | ($6,005) | | **Net cash from investing activities** | ($826) | ($1,000) | | **Net cash from financing activities** | $947 | ($4,242) | | **Net change in cash** | ($18,780) | ($11,791) | | **Cash at end of period** | $22,802 | $25,173 | [Non-GAAP Financial Measures and Reconciliations](index=11&type=section&id=Use%20of%20Non-GAAP%20Financial%20Measures) This section defines and reconciles non-GAAP metrics, including Organic Revenue Growth and Adjusted EBITDA, for core operating performance insight [Use of Non-GAAP Financial Measures](index=11&type=section&id=Use%20of%20Non-GAAP%20Financial%20Measures_definitions) The company defines 'organic revenue' and 'Adjusted EBITDA' as non-GAAP measures for better performance trend analysis and operating evaluation - The company uses "organic revenue growth" to compare performance excluding the significant impact of acquisitions and divestitures, allowing for better evaluation of long-term trends[24](index=24&type=chunk) - Adjusted EBITDA is used by management for operating performance evaluation and planning, as it excludes certain cash and non-cash items not considered part of ongoing operations[26](index=26&type=chunk) [Reconciliation of Net Loss to Adjusted EBITDA](index=13&type=section&id=Reconciliation%20of%20Net%20(Loss)%20Income%20to%20Adjusted%20EBITDA%20(unaudited)) Q1 2025 GAAP net loss of $3.3 million reconciled to non-GAAP Adjusted EBITDA of $19.2 million, primarily adjusted for depreciation and equity compensation Reconciliation of Net Loss to Adjusted EBITDA (Q1 2025, in thousands) | Description | Amount | | :--- | :--- | | **Net loss** | **($3,322)** | | Interest expense, net | $7,509 | | Income tax benefit, net | ($95) | | Depreciation and amortization | $11,865 | | Equity compensation | $2,414 | | Other adjustments | $841 | | **Adjusted EBITDA** | **$19,212** | [Reconciliation of Other GAAP to Non-GAAP Measures](index=14&type=section&id=Reconciliation%20of%20Other%20Reported%20GAAP%20Measures%20to%20Non-GAAP%20Measures) This section reconciles Q1 2025 GAAP metrics to non-GAAP counterparts, including Gross Margin and Net Loss to Net Income Q1 2025 GAAP to Non-GAAP Reconciliation | Metric | Reported GAAP | Non-GAAP Measure | | :--- | :--- | :--- | | **Gross Profit** | $83.1M (67.0%) | $93.3M (75.3%) | | **Operating Income** | $4.9M (3.9%) | $17.7M (14.3%) | | **Net (Loss) Income** | ($3.3M) | $6.2M | | **EPS** | ($0.04) | $0.08 | [Forward-Looking Statements](index=4&type=section&id=Legal%20Notice%20Regarding%20Forward-Looking%20Statements) This section cautions that forward-looking statements are subject to risks, including tariffs, supply chain issues, and regulatory changes - The press release contains forward-looking statements about future performance and strategy, which are subject to inherent risks and uncertainties[14](index=14&type=chunk) - Key risks that could impact future results include tariffs, failure to realize benefits from the Advanced Rehabilitation Business divestiture, supply chain disruptions, debt covenants, and potential FDA reclassification of products[15](index=15&type=chunk)[16](index=16&type=chunk) ```

Core Viewpoint - Bioventus Inc. reported a decline in revenue for the first quarter of 2025, primarily due to the divestiture of its Advanced Rehabilitation Business, but achieved organic revenue growth across all business segments, indicating resilience in its strategic execution despite macroeconomic challenges [2][6]. Financial Performance - Worldwide revenue for Q1 2025 was $123.9 million, a decrease of 4.3% from $129.5 million in the same period last year, largely impacted by the divestiture [2][5]. - Organic revenue increased by 5.0%, reflecting positive growth across all three business segments [2][6]. - The net loss attributable to Bioventus Inc. was $2.6 million, an improvement from a net loss of $4.9 million in the prior-year period [3][4]. - Adjusted EBITDA for the quarter was $19.2 million, down from $22.6 million in the previous year, primarily due to the divestiture and planned growth investments [3][6]. Revenue Breakdown by Business - U.S. revenue from Pain Treatments was $52.7 million, up 4.0% year-over-year, while Surgical Solutions revenue increased by 6.5% to $40.8 million [5][8]. - Restorative Therapies revenue fell by 32.9% to $17.0 million, significantly affected by the divestiture of the Advanced Rehabilitation Business [5][9]. - International revenue totaled $13.4 million, a decline of 12.0%, with Pain Treatments and Surgical Solutions showing modest growth, while Restorative Therapies revenue dropped by 47.1% [5][9]. Strategic Developments - The company reiterated its financial guidance for 2025, expecting net sales between $560 million and $570 million, reflecting organic growth of approximately 6.1% to 8.0% when accounting for the divestiture [10][13]. - Adjusted EBITDA guidance for 2025 is set between $112 million and $116 million, indicating a potential increase in Adjusted EBITDA margin compared to 2024 [10][13]. - Non-GAAP EPS is projected to be between $0.64 and $0.68, representing a growth of 30.6% to 38.8% [10][13].

Core Viewpoint - Bioventus Inc. will report its financial results for Q1 of fiscal year 2025 on May 6, 2025, before market opening, followed by a conference call for discussion [1] Group 1: Financial Reporting - The financial results for the first quarter of fiscal year 2025 will be announced before the market opens on May 6, 2025 [1] - A conference call will be held at 8:30 a.m. Eastern Time on the same day to discuss the results and provide a business update [1] Group 2: Conference Call Participation - Participants can join the conference call by dialing 1-833-636-0497 and referencing the Bioventus Inc. Conference Call [2] - A live webcast of the call will be available on the Company's Investor Relations website, with an archive for replay until May 5, 2026 [2] Group 3: Company Overview - Bioventus is a global leader in innovations for active healing, providing clinically proven and cost-effective products for quick and safe healing [3] - The company's mission focuses on helping patients resume active lives through offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [3] - Bioventus emphasizes high quality standards, evidence-based medicine, and ethical behavior, positioning itself as a trusted partner for physicians worldwide [3]

Industry Overview - The U.S. healthcare sector is facing challenges due to technological innovation, policy shifts, financial pressures, and changing consumer expectations [1] - The sector has underperformed compared to the S&P 500, growing only 2.5% in 2024 versus the benchmark's 23.3% increase [2] - Total U.S. healthcare spending has increased from $1.4 trillion in 2000 to $4.9 trillion in 2023, despite the healthcare sector's weighting in the S&P 500 dropping to a 25-year low of about 10% [3] Growth Drivers - An aging population and rising health issues like obesity and diabetes are contributing to sector growth [4] - Key areas such as telehealth, surgery, data analytics, and biotechnology are experiencing significant advancements [3] - The integration of AI in medical research is expected to drive long-term changes in the sector [5] Investment Opportunities - Stocks like Bioventus Inc. (BVS), Amicus Therapeutics, Inc. (FOLD), Rigel Pharmaceuticals, Inc. (RIGL), and The Ensign Group, Inc. (ENSG) are identified as having potential for growth [2] - Bioventus has an expected earnings growth rate of 34.7% for the current year, with a Zacks Consensus Estimate improvement of 43.5% [7] - Amicus Therapeutics shows an expected earnings growth rate of 116.7%, with a 20.9% improvement in earnings estimates [8] - Rigel Pharmaceuticals has an expected earnings growth rate of 20.2%, with a 13.3% improvement in earnings estimates [9] - Ensign Group has an expected earnings growth rate of 13.5%, with a 1.5% improvement in earnings estimates [10]

Group 1: Price Trend and Technical Analysis - Bioventus (BVS) has experienced a bearish price trend, losing 6.4% over the past week, but a hammer chart pattern suggests a potential trend reversal as bulls may have gained control [1] - The hammer pattern indicates a nearing bottom with likely subsiding selling pressure, supported by strong agreement among Wall Street analysts in raising earnings estimates for BVS [2][7] - The hammer pattern forms when there is a small candle body with a long lower wick, signaling that bears may have lost control and indicating a potential trend reversal [4][5] Group 2: Earnings Estimates and Analyst Consensus - There has been an upward trend in earnings estimate revisions for BVS, which is a bullish indicator as it typically leads to price appreciation [7] - The consensus EPS estimate for the current year has increased by 43.5% over the last 30 days, indicating strong agreement among analysts regarding the company's improved earnings potential [8] - BVS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, suggesting it is likely to outperform the market [9]

Core Viewpoint - Bioventus (BVS) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to institutional investors adjusting their valuations, resulting in stock price movements [4]. Company Performance Indicators - Bioventus is projected to earn $0.66 per share for the fiscal year ending December 2025, reflecting a year-over-year increase of 34.7% [8]. - Over the past three months, the Zacks Consensus Estimate for Bioventus has risen by 37.5%, indicating a positive trend in earnings expectations [8]. Zacks Rank System - The Zacks Rank system categorizes stocks based on earnings estimate revisions, with only the top 20% of stocks receiving a 'Strong Buy' or 'Buy' rating, suggesting superior potential for market-beating returns [9][10]. - The upgrade of Bioventus to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a favorable outlook for the stock's performance in the near term [10].